Seer Debt to Equity Ratio 2020-2022 | SEER

Current and historical debt to equity ratio values for Seer (SEER) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Seer debt/equity for the three months ending March 31, 2022 was 0.00.
Seer Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.04B $0.49B 0.08
2021-12-31 $0.04B $0.50B 0.07
2021-09-30 $0.01B $0.52B 0.03
2021-06-30 $0.01B $0.53B 0.02
2021-03-31 $0.01B $0.54B 0.02
2020-12-31 $0.01B $0.43B 0.03
2020-09-30 $0.00B $0.00B 0.00
2020-06-30 $0.00B $0.00B 0.00
2020-03-31 $0.00B $0.00B 0.00
2019-12-31 $0.01B $0.09B 0.06
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.559B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00